2022 is shaping up to be an interesting year for Pharma/Biotech companies and their commercial and government pricing strategies and contracts. There are multiple policies and rules being discussed, already proposed, under review, in litigation, and that need to be implemented starting this month! Join our 6 experts in this kick-off to 2022, with a live discussion to review the evolving healthcare policy and GP regulations and hear their thoughts on how they will affect you and your company. Key topics they will discuss:
- 340B
- Impacts from the Build Back Better Act
- Next Gen GPO’s including Safe Harbor and AKS
- Line Extension identification and evaluations
- Co-Pay Maximizers and PBM Accumulators
- Changes to Federal and State Drug Pricing, Reimbursement and Transparency
Date: Wednesday, January 26
Time: 12:00 – 1:00 pm EST
Confirmed Speakers
- Mike Kurland, Vice President, Revenue Management & Compliance Solutions, EVERSANA
- Jeremy Docken, Founder/CSO, Kalderos
- Jennifer English, Executive Director, Customer Finance & Price Reporting, Eisai Inc.
- Stephanie Kupski, Director US Pricing & Government Reporting, CSL Behring
- Meena Datta, Partner, Sidley Austin
- David Farber, Partner, King & Spalding